Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration ...

GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...

Metallic nanoparticles injected into the retina partly restored vision in blind mice and could work as a treatment for ...

Can AI really replace scientists? Robin, an AI system, identified a potential drug for vision loss, but scientists are ...

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and ...

The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of 2 tissue ...

Instead of receiving uncomfortable eye injections around once a month for a disease that can lead to blindness, patients may ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Newmedica has invested £3m in the opening of a new centre based in Welwyn Garden City, which it says aims to support local ...

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...